search

Active clinical trials for "Hematologic Neoplasms"

Results 791-800 of 1132

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic Malignancies

Withdrawn43 enrollment criteria

Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies

Lymphoid Hematological MalignanciesUmbilical Cord Blood Transplant

The purpose of this study is to determine the safety and effectiveness of UCBT to treat patients with lymphoid hematological diseases and to see if this treatment can decrease the incidence of leukemia relapse, GVHD and infections. These patients have a type of blood cell disorder that is very hard to cure. This treatment that is being used in this trial is known as a stem cell transplant. This treatment might help the patient live longer without the disease. It uses much stronger doses of drugs and radiation to kill the diseased cells that could be given without the transplant. We also think that the healthy cells from the donor may help fight any diseased cells left after the transplant. For the transplant to take place, we will administer stem cells from a 'donor' whose cells best 'match' the patient's. In this study umbilical cords will be the source of the stem cells. Before the transplant, two very strong drugs plus total body irradiation will be given to as preconditioning. This treatment will kill most of your blood-forming cells in the bone marrow. The patient will then get then healthy stem cells. If the patient has the disease in the central nervous system (CNS), they will receive radiation to the head and spine before starting the conditioning. This is to try to get disease control in the CNS. Radiation will not be given for children under 2 yrs old. Currently, many umbilical cord blood units are available in public banks for transplantation in patients lacking bone marrow donors. UCB transplants (UCBT) may offer several advantages over adult bone marrow or peripheral blood stem cell transplants, including: rapid availability, absence of donor risk, low risk of transmissible infectious diseases, low risk of acute GvHD (Graft vs. Host Disease) The three main causes of death after umbilical cord blood transplantation for these kind of disorders are graft failure, infection and disease relapse. In this study we are trying to address these three problems: To help improve engraftment we will add the drug Fludarabine to Cytoxan and total body irradiation. Fludarabine is a very strong medicine. We will try to decrease infections and reduce leukemia relapse by using fludarabine instead of antithymocyte globulin (ATG).

Withdrawn11 enrollment criteria

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

Hematologic MalignancyAML5 more

The purpose of this trial is to determine if selectively removing only a small subset of T cells, called CD8+ T cells, is safe and if it can reduce the risk of graft versus host disease (GVHD) without losing the anti-cancer effects.

Completed24 enrollment criteria

Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19...

COVID19Hematologic Malignancy

The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.

Withdrawn16 enrollment criteria

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies...

Acute Myeloid Leukemia

To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. To evaluate the preliminary efficacy of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.

Withdrawn29 enrollment criteria

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer....

Relapsed Hematologic MalignancyRefractory Hematologic Malignancy

This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced. They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma. Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatment (known as relapsed) and when other treatment no longer works (known as refractory). Combining tazemetostat with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.

Withdrawn33 enrollment criteria

Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion...

Transplant-Related Hematologic Malignancy

Therapeutic exploratory study to evaluate safety, open, nonrandomized, multicentre, prospective, of cohort of patients who will receive different doses of allo-depleted lymphocytes . This project joins in this pioneering worldwide initiative with its own technology based on the use of proteasome inhibitors in vitro, which advantages are, over other methods described, the continuing viability of regulatory T cells and the use of a product to generate allo-depletion that, contrary to those reported by other research groups, it does not pose problems from the point of view of its use or toxicity as we employ a drug widely used clinically by intravenous administration.

Withdrawn13 enrollment criteria

Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological...

Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma

This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 2 or higher oral mucositis.

Completed22 enrollment criteria

CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation

Haematological MalignanciesAllogeneic Stem Cell Transplant1 more

The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic stem cell transplantation.

Withdrawn11 enrollment criteria

Therapy for Progressive and/or Refractory Hematologic Malignancies

CancerHematologic Malignancies

The purpose of this study is to evaluate the safety and effectiveness of Tumor Associated Peptide Antigen (TAPA) pulsed dendritic cell (DC) vaccines in the treatment of progressive and/or refractory hematologic malignancies (HM). We hypothesize that treatment of patients with relapsed and/or refractory HM, without available potentially curative treatment options, and whose neoplastic cells express at least one (1) TAPA of a defined panel of TAPAs, using low-dose cyclophosphamide (CYP) followed by an autologous, monocyte-derived, TAPA-pulsed DC vaccine and low-dose granulocyte macrophage colony stimulating factor (GM-CSF), will result in TAPA-specific T-cell responses without significant toxicities. We also hypothesize CD4+ T-cell and CD8+ T-cell responses generated against specific TAPAs may translate into clinical antitumor activity.

Withdrawn31 enrollment criteria
1...798081...114

Need Help? Contact our team!


We'll reach out to this number within 24 hrs